Recent Patents on Anti-Infective Drug Discovery

Dieter Kabelitz  
Institute of Immunology
Universitätsklinikum Schleswig-Holstein
Campus Kiel


Poxvirus Cancer Therapy

Author(s): Philippe-Alexandre Gilbert and Grant McFadden

Affiliation: New Emerging Pathogens Initiative, Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL. USA 32610.


Despite many advances in chemotherapy and other medical techniques, patients with cancer often develop local recurrence or metastatic spread. Recent advances in molecular biology and tumor immunology have led to the design of many new anti-tumor vaccines. Such approaches are now using recombinant viruses to treat different types of cancer. From these new developments, innovative fields are emerging: vaccine virotherapy, viral immunotherapy, oncolytic virotherapy and drug virotherapy. Many viruses are currently exploited as recombinant vectors and each offers natural or synthetic characteristics that may provide unique means to treat cancer. Poxviruses are large double stranded DNA viruses that offer many advantageous characteristics as recombinant vectors. Poxvirus-based vectors offer essentially unlimited possibilities for genetic manipulation due to the large size of their DNA and high degree of safety. Vaccinia virus, the prototype virus of the Orthopoxvirus genus that was extensively used to eradicate Smallpox, and other poxviruses are now being considered and used for the treatment of cancer. This review will cover their utilization as anti-cancer therapeutics by describing recent patents (2000-2005).

Keywords: Poxvirus, cancer, vaccine, virotherapy, immunotherapy, oncolytic virus, vaccinia virus, MVA, canarypox, fowlpox

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [309 - 321]
Pages: 13
DOI: 10.2174/157489106778777592
Price: $100